Trials / Terminated
TerminatedNCT00141310
Sildenafil Citrate for the Treatment of Established Pre-Eclampsia
A Randomised, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study to Evaluate the Efficacy, Safety and Toleration of Oral Sildenafil Citrate Administered in the Dose Range of 20 - 80 Mg TID for the Treatment of Pre-Eclampsia. (PET)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 76 (planned)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the efficacy and safety of sildenafil citrate in the treatment of established pre-eclampsia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sildenafil citrate |
Timeline
- Start date
- 2004-09-01
- Completion
- 2006-04-01
- First posted
- 2005-09-01
- Last updated
- 2021-02-01
Locations
10 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00141310. Inclusion in this directory is not an endorsement.